Toxicities Associated with Head and Neck Cancer Treatment and Oncology-Related Clinical Trials

Approximately 600,000 new cases of head and neck cancer will be diagnosed worldwide this year. Of those, a bit less than 10% will occur in the United States.1 The majority of these neoplasms will be histologically diagnosed as squamous cell carcinomas for which the preferred treatment typically consists of a multi-modality approach which includes local resection followed by a course of concomitant chemoradiation in which radiosensitizing chemotherapy (most commonly cisplatin) is coupled with cumulative radiation doses of 60Gy – 70Gy given in 1.8Gy – 2.2Gy daily fractions.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research